Trv Gp Vi LLC Takes Position in Rapport Therapeutics, Inc. $RAPP

Trv Gp Vi LLC purchased a new position in shares of Rapport Therapeutics, Inc. (NASDAQ:RAPP - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 969,218 shares of the company's stock, valued at approximately $40,387,314. Rapport Therapeutics comprises about 0.0% of Trv Gp Vi LLC's investment portfolio, making the stock its 3rd biggest position. Trv Gp Vi LLC owned about 2.02% of Rapport Therapeutics at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Rapport Therapeutics by 86.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,887 shares of the company's stock worth $99,000 after acquiring an additional 4,582 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC purchased a new stake in Rapport Therapeutics during the 1st quarter valued at approximately $2,039,000. Rhumbline Advisers increased its stake in Rapport Therapeutics by 40.1% in the first quarter. Rhumbline Advisers now owns 14,358 shares of the company's stock worth $144,000 after purchasing an additional 4,109 shares during the period. Geode Capital Management LLC grew its stake in Rapport Therapeutics by 5.5% during the 2nd quarter. Geode Capital Management LLC now owns 333,159 shares of the company's stock worth $3,789,000 after buying an additional 17,496 shares during the last quarter. Finally, Creative Planning purchased a new stake in Rapport Therapeutics in the 2nd quarter worth approximately $121,000.

Insider Activity

In related news, CEO Abraham Ceesay sold 28,958 shares of Rapport Therapeutics stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $48.01, for a total value of $1,390,273.58. Following the sale, the chief executive officer owned 486,108 shares of the company's stock, valued at approximately $23,338,045.08. This trade represents a 5.62% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last 90 days, insiders have sold 73,034 shares of company stock valued at $3,484,157. 12.48% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on RAPP shares. UBS Group reiterated a "strong-buy" rating on shares of Rapport Therapeutics in a research note on Monday, August 17th. Raymond James Financial reiterated a "strong-buy" rating and issued a $75.00 price objective on shares of Rapport Therapeutics in a report on Monday, August 17th. William Blair started coverage on shares of Rapport Therapeutics in a report on Tuesday, July 28th. They issued an "outperform" rating for the company. Weiss Ratings reissued a "sell (d-)" rating on shares of Rapport Therapeutics in a research report on Friday, July 17th. Finally, Wall Street Zen downgraded Rapport Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, August 8th. Two research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Rapport Therapeutics presently has a consensus rating of "Buy" and an average target price of $62.86.

Rapport Therapeutics Stock Performance

Shares of NASDAQ RAPP traded down $1.20 during mid-day trading on Friday, reaching $49.63. The company's stock had a trading volume of 116,513 shares, compared to its average volume of 342,401. The stock has a 50-day moving average of $43.17 and a two-hundred day moving average of $36.79. Rapport Therapeutics, Inc. has a 1-year low of $14.11 and a 1-year high of $52.93. The stock has a market capitalization of $2.38 billion, a P/E ratio of -16.33 and a beta of 0.97.

Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($1.19) earnings per share for the quarter, missing analysts' consensus estimates of ($1.12) by ($0.07). Analysts predict that Rapport Therapeutics, Inc. will post -4.09 EPS for the current fiscal year.

Rapport Therapeutics Company Profile

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.

Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.